Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLARIUS: Bevacizumab + radiotherapy vs temozolomide + radiotherapy in newly diagnosed glioblastoma with unmethylated MGMT promoter
2009-010390-21Phase 2Completed
- Sponsor
- Roche
- Start
- Sep 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab, irinotecan and temozolomide in glioblastoma (GBM) (2 arms), sponsored by Roche. Primary endpoint: progression-free survival at 6 months (EFS6) after randomization. Started Sep 2009; status: completed.
02
Drugs
bevacizumabirinotecantemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2009-010390-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010390-21.